Latest Manufacturing News

Energy Technologies Limited reported a 17.5% increase in unaudited sales revenue for 2Q FY2025, driven by a new cable supply contract and a robust order book, signaling positive momentum amid a strategic business plan revision.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Ionic Rare Earths reports strong progress on its Belfast rare earth oxide recycling facility, backed by a robust feasibility study and UK government grant applications, alongside strategic developments in Brazil and Uganda.

Wide Open Agriculture reports a 50% reduction in overheads alongside the development of a novel lupin-based tofu product, positioning itself for growth in the global plant protein market.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Lode Resources has completed the acquisition of the Montezuma Antimony Project in Tasmania, delivering high-grade drill results that bolster its strategy to become a leading Australian antimony producer amid global supply shortages.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.

Althea Group Holdings reported a 20% increase in customer receipts to $9.01 million for Q2 FY25, while addressing governance lapses and reviewing its FY25 guidance. The company is advancing operational improvements and cost savings as it prepares for a pivotal Federal Court hearing.